General features and epidemiology of lymphoma in Colombia. A multicentric study

被引：6

作者：

Combariza, Juan F. ^{[1
]}

Lombana, Milton ^{[2
]}

Torres, Ana M. ^{[2
]}

Castellanos, Ana M. ^{[3
]}

Arango, Marcos ^{[1
]}

机构：

[1] Hosp Pablo Tobon Uribe, Dept Hematol, Medellin, Colombia

[2] Clin Imbanaco, Hematol Oncol Dept, Cali, Colombia

[3] Hosp Mil Cent, Hematol Oncol Dept, Bogota, Colombia

来源：

ANNALS OF HEMATOLOGY | 2015年 / 94卷 / 06期

关键词：

Lymphoma; Hodgkin lymphoma; Non-Hodgkin lymphoma; Colombia; NON-HODGKIN-LYMPHOMA; B-CELL LYMPHOMA; CANCER REGISTRY; UNITED-STATES; CLASSIFICATION; RITUXIMAB; CYCLOPHOSPHAMIDE; VINCRISTINE; DOXORUBICIN; OUTCOMES;

D O I：

10.1007/s00277-015-2301-7

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The relative frequency of the non-Hodgkin lymphoma (NHL) subtypes varies around the world. The objective of this study was to describe the general features of patients with lymphoma in Colombia. A total of 819 patients with a new diagnosis of lymphoma were included. Nighty-nine (12 %) of them had Hodgkin lymphoma (HL) and 720 (88 %) had NHL. Most cases had advanced stage disease at presentation (63.6 %). Diffuse large B cell lymphoma (DLBCL) was the most frequent diagnosis; it was seen in 40 % of patients with NHL and in 35 % of patients in the whole series. Overall survival rates at 3 years were 77 % for HL and follicular lymphoma, 54 % for DLBCL, and 45 % for T cell lymphomas. In conclusion, the distribution of specific NHL subtypes is similar to what has been reported previously in other tropical countries.

引用

页码：975 / 980

页数：6

共 26 条

[1] Epidemiology of the non-Hodgkin's lymphomas: Distributions of the major subtypes differ by geographic locations [J].

Anderson, JR ;

Armitage, JO ;

Weisenburger, DD .

ANNALS OF ONCOLOGY, 1998, 9 (07) :717-720

[2] Endemic Burkitt's lymphoma as a polymicrobial disease New insights on the interaction between Plasmodium falciparum and Epstein-Barr virus [J].

Chene, Arnaud ;

Donati, Daria ;

Orem, Jackson ;

Bjorkman, Anders ;

Mbidde, E. R. ;

Kironde, Fred ;

Wahlgren, Mats ;

Bejarano, Maria Teresa .

SEMINARS IN CANCER BIOLOGY, 2009, 19 (06) :411-420

[3] Revised response criteria for malignant lymphoma [J].

Cheson, Bruce D. ;

Pfistner, Beate ;

Juweid, Malik E. ;

Gascoyne, Randy D. ;

Specht, Lena ;

Horning, Sandra J. ;

Coiffier, Bertrand ;

Fisher, Richard I. ;

Hagenbeek, Anton ;

Zucca, Emanuele ;

Rosen, Steven T. ;

Stroobants, Sigrid ;

Lister, T. Andrew ;

Hoppe, Richard T. ;

Dreyling, Martin ;

Tobinai, Kensei ;

Vose, Julie M. ;

Connors, Joseph M. ;

Federico, Massimo ;

Diehl, Volker .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (05) :579-586

[4] Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles [J].

Cunningham, David ;

Hawkes, Eliza A. ;

Jack, Andrew ;

Qian, Wendi ;

Smith, Paul ;

Mouncey, Paul ;

Pocock, Christopher ;

Ardeshna, Kirit M. ;

Radford, John A. ;

McMillan, Andrew ;

Davies, John ;

Turner, Deborah ;

Kruger, Anton ;

Johnson, Peter ;

Gambell, Joanna ;

Linch, David .

LANCET, 2013, 381 (9880) :1817-1826

[5] Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease [J].

Diehl, V ;

Franklin, J ;

Pfreundschuh, M ;

Lathan, B ;

Paulus, U ;

Hasenclever, D ;

Tesch, H ;

Herrmann, R ;

Dörken, B ;

Müller-Hermelink, H ;

Dühmke, E ;

Loeffler, M .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (24) :2386-2395

[6] Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial [J].

Hallek, M. ;

Fischer, K. ;

Fingerle-Rowson, G. ;

Fink, A. M. ;

Busch, R. ;

Mayer, J. ;

Hensel, M. ;

Hopfinger, G. ;

Hess, G. ;

von Gruenhagen, U. ;

Bergmann, M. ;

Catalano, J. ;

Zinzani, P. L. ;

Caligaris-Cappio, F. ;

Seymour, J. F. ;

Berrebi, A. ;

Jaeger, U. ;

Cazin, B. ;

Trneny, M. ;

Westermann, A. ;

Wendtner, C. M. ;

Eichhorst, B. F. ;

Staib, P. ;

Buehler, A. ;

Winkler, D. ;

Zenz, T. ;

Boettcher, S. ;

Ritgen, M. ;

Mendila, M. ;

Kneba, M. ;

Doehner, H. ;

Stilgenbauer, S. .

LANCET, 2010, 376 (9747) :1164-1174

[7] Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone:: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group [J].

Hiddemann, W ;

Kneba, M ;

Dreyling, M ;

Schmitz, N ;

Lengfelder, E ;

Schmits, R ;

Reiser, M ;

Metzner, B ;

Harder, H ;

Hegewisch-Becker, S ;

Fischer, T ;

Kropff, M ;

Reis, HE ;

Freund, M ;

Wörmann, B ;

Fuchs, R ;

Planker, M ;

Schimke, J ;

Eimermacher, H ;

Trümper, L ;

Aldaoud, A ;

Parwaresch, R ;

Unterhalt, M .

BLOOD, 2005, 106 (12) :3725-3732

[8] Classification of non-Hodgkin lymphoma in Central and South America: a review of 1028 cases [J].

Laurini, Javier A. ;

Perry, Anamarija M. ;

Boilesen, Eugene ;

Diebold, Jacques ;

MacLennan, Kenneth A. ;

Mueller-Hermelink, H. Konrad ;

Nathwani, Bharat N. ;

Armitage, James O. ;

Weisenburger, Dennis D. .

BLOOD, 2012, 120 (24) :4795-4801

[9] Incidence, clinical characteristics and survival of malignant lymphomas: a population-based study from a cancer registry in northern Italy [J].

Luminari, Stefano ;

Cesaretti, Marina ;

Rashid, Ivan ;

Mammi, Caterina ;

Montanini, Antonella ;

Barbolini, Elisa ;

Bellei, Monica ;

Pennese, Elsa ;

Sirotti, Maria Angela ;

Marcheselli, Luigi ;

Partesotti, Giovanni ;

Bari, Alessia ;

Maiorana, Antonino ;

Bonacorsi, Goretta ;

Federico, Massimo .

HEMATOLOGICAL ONCOLOGY, 2007, 25 (04) :189-197

[10] Transformation of Indolent B-Cell Lymphomas [J].

Montoto, Silvia ;

Fitzgibbon, Jude .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (14) :1827-1834

← 1 2 3 →